An Open-Label, parallel-group, multicenter Phase I study to investigate the pharmacokinetics of NKTR-102 (Etirinotecan pegol) in patients with advanced or metastatic solid tumors and reduced hepatic function
|Effective start/end date||5/30/13 → 8/30/18|
- NEKTAR THERAPEUTICS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.